Tempus AI, Inc

Tempus AI, Inc (NASDAQ: TEM) is a technology-driven company focused on enhancing precision medicine by leveraging artificial intelligence in the healthcare sector. It offers AI-powered solutions that assist physicians in providing individualized patient care, while also supporting the discovery, development, and distribution of targeted therapies.

Business Updates

• A History of Hype and Financial Controversy: Tempus AI’s leadership, particularly CEO Eric Lefkofsky, has a track record that raises significant red flags. The Spruce Point Capital report details how previous ventures led by Lefkofsky and his associates—such as Starbelly.com, Groupon, and InnerWorkings—suffered from financial restatements, regulatory scrutiny, and dramatic stock price declines. These companies were often promoted with grand technological narratives that ultimately failed to deliver on their promises. Tempus appears to follow a similar trajectory, emphasizing cutting-edge AI capabilities in healthcare despite limited revenue derived from these initiatives.
• Questionable Financial Engineering and Related Party Dealings: The company’s financial structure and partnerships have also come under scrutiny. Notably, the AstraZeneca and Pathos AI agreements are portrayed as strategic expansions but may in fact reflect declining genuine customer interest. Spruce Point alleges that payments from AstraZeneca to Tempus are routed to Pathos, a company tied closely to Tempus insiders, and involve non-cash considerations such as preferred stock. This arrangement creates the appearance of revenue while potentially inflating Tempus’s reported Total Contract Value (TCV) by hundreds of millions of dollars. Furthermore, Tempus’s mark-to-zero valuation of its 15% stake in Pathos contradicts its promotional claims, reinforcing concerns about transparency and economic substance.
• Dubious AI Credibility and Product Functionality: Tempus’s rebranding as an “AI” company is undermined by the reality that AI applications account for less than 2% of total revenue. Spruce Point highlights inconsistencies in the company’s product demonstrations, showing clear data validation failures in its HUB platform—including mismatched patient information and illogical sample processing timelines. Such issues cast doubt on the effectiveness of its AI in supporting critical healthcare decisions. These technical shortcomings, paired with exaggerated marketing claims, suggest that the AI label may be more of a branding exercise than a reflection of true innovation.
• Aggressive Accounting and Revenue Recognition Practices: The report outlines how Tempus’s accounting choices—especially regarding Adjusted EBITDA and revenue recognition—may be artificially enhancing its financial profile. One key example involves a USD 250 million Google Cloud promissory note, which Tempus offsets against SG&A expenses to inflate its EBITDA. Similarly, billing practices through ambiguous codes like 81479 raise concerns about the legitimacy of Tempus’s revenue growth, particularly following its acquisition of Ambry Genetics. The company’s reliance on stock-based compensation and its need to meet a USD 1 billion revenue covenant add further pressure to maintain inflated top-line figures.
• Leadership and Governance Raise Red Flags: Concerns also extend to governance, with several board members and executives having been previously linked to companies that faced SEC charges, financial restatements, or internal control failures. For instance, Tempus’s Audit Chair and CAO held similar roles at firms implicated in accounting scandals, such as InnerWorkings and Surgalign. These associations, combined with selective biographical disclosures that omit controversial past roles, suggest a pattern of omitting critical information that investors might find material. The report concludes that such governance weaknesses only amplify the financial and operational concerns facing Tempus.
• AI Revenue Lags Behind the Brand’s Bold Claims: Despite rebranding itself as "Tempus AI," the company’s actual revenue from AI-specific applications remains alarmingly low. In 2024, AI-related revenue totaled only USD 12.4 million—less than 2% of its USD 693.4 million in total revenue. This negligible figure stands in stark contrast to the company's public positioning as a leader in AI-enabled healthcare. The disparity suggests that the rebranding may be more of a marketing maneuver designed to ride the broader market enthusiasm for AI rather than a reflection of substantive product advancement. Compounding these concerns, product demonstrations reveal basic software issues—such as mismatched patient data and logically impossible test sequences—that undermine claims of cutting-edge AI capabilities.

Technical Observation (on the daily chart):

TEM is showing signs of a short-term uptrend, having recently bounced off its 50-day moving average (USD 52.61) and currently at USD 54.55. While it remains below the 21-day MA (USD 59.83), the trend is supported by rising volume and a neutral RSI (46.58), indicating room for further upside. A recent cross (21-day MA crossing above 50-day MA) adds a bullish signal. Key resistance lies around USD 59.83, with support near USD 52.60. A breakout above resistance could confirm continued bullish momentum.

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is May 29,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.